Curasight
↗Copenhagen, Denmark
Curasight is a Danish clinical-stage biotech company pioneering the development of novel cancer diagnostics and therapeutics based on uPAR Theranostics technology. The company was founded in 2013 in Copenhagen on the foundation of over 10 years of nuclear medicine research conducted at Rigshospitalet (Copenhagen University Hospital). Curasight's proprietary uPAR platform combines two complementary approaches: uTRACE®, a PET imaging diagnostic tool for precise tumor characterization and risk stratification, and uTREAT®, a targeted radiotherapy for more gentle and efficient cancer treatment that minimizes irradiation of healthy tissue. The company is developing a pipeline of products to address multiple cancer indications with unmet treatment needs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue / Early-stage clinical development
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Clinical Stage
Total Raised:~DKK 300M+ (estimated cumulative)
Investors:Fenja Capital II, PreSeed Ventures, Seed Capital, Curium Inc.
STOCK
Exchange:Spotlight Stock Market
Ticker:CURAS
PIPELINE
Stage:Phase 1-2 Clinical
Lead Drug Stage:uTREAT Phase 1 (Glioblastoma) and uTRACE Phase 2 (Prostate Cancer)
Modalities:Radiopharmaceutical, Targeted Radiotherapy, PET Imaging, Theranostic
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Curium Inc. (global license and collaboration for uTRACE in prostate cancer; manufacturing and commercialization partner), Premier Research LLC (CRO for Phase 1 uTREAT trial), Rigshospitalet (research collaboration)
COMPETITION
Position:Emerging|Niche Player
Competitors:Point Biopharma (acquired by Eli Lilly for USD 1.4B), Mariana Oncology (acquired by Novartis for USD 1B+), Fusion Pharmaceuticals (acquired by AstraZeneca for USD 2.4B), Aktis Oncology (partnered with Eli Lilly, USD 1.1B deal), Radionetics Oncology (option deal with Eli Lilly, USD 1B)
LEADERSHIP
Key Executives:
Ulrich Krasilnikoff - CEO and CFO
Andreas Kjær - Co-founder, CSO, Board Member
Morten Persson - Co-founder and CEO
Scientific Founders:Andreas Kjær, Morten Persson, Jacob Madsen, Carsten Haagen Nielsen
Board Members:Per Falholt (Board Member), Lars Trolle (Deputy Chairman / Vice-Chairman), Kirsten Drejer (Board Member), Charlotte Vedel (Board Member), Andreas Kjær (Board Member, Co-founder), Ulrich Krasilnikoff (Board Member, CEO)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Curasight. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.